ArticleBlood2026
DOT1L shapes ncPRC1 target gene repression to maintain germinal center B-cell identity in diffuse large B-cell lymphoma.
Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractGerminal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) depends on the cooperative activity of the histone methyltransferases DOT1L and EZH2 to maintain its proproliferative GCB identity while repressing plasma cell (PC) differentiation. To explore the mechanisms underlying the codependency between DOT1L and EZH2 in GCB-DLBCL, we performed an EZH2 inhibitor (EZH2i)-anchored genome-wide CRISPR interference screen and identified multiple candidate genes encoding components of noncanonical Polycomb repressor complex 1 (ncPRC1), including USP7, KDM2B, RING1, and PCGF1. We identified USP7 (ubiquitin-specific protease 7) as a potential direct target of DOT1L, and its downregulation was associated with increased EZH2i sensitivity in multiple GCB-DLBCL cell lines. Furthermore, we observed that DOT1L influences the composition of chromatin-bound ncPRC1 and, in part, regulates the deposition of H2AK119 monoubiquitination (H2AK119ub1) at gene promoters co-occupied by H3K27 trimethylation (H3K27me3), here defined as PRC1/2 targets. These PRC1/2 targets were specifically enriched in PC signature genes, and their derepression was associated with DOT1L inhibition-mediated loss of H2AK119ub1. This study provides novel insights into the role of DOT1L and its functional codependency with EZH2 in maintaining GCB identity in DLBCL and supports a model in which concurrent reduction of H2AK119ub1 and H3K27me3 promotes differentiation toward an antiproliferative, PC-like state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.